Abstract
Introduction: Physical activity (PA) is a lifestyle factor related to morbidity and mortality in many chronic diseases such as asthma. Little is known about the consequences of severe asthma (SA) on PA and no studies are available on the improvement of PA in SA patients treated with biologics.
Aims and Objectives: The aims of this study were to evaluate the PA characterization of SA patients and to compare the PA patterns between SA patients treated with traditional therapies (TT) and those treated with biologics (BT) (mepolizumab/omalizumab).
Methods: A prospective observational study was performed in SA stable patients, divided into two groups: TT and BT. PA parameters (number of steps/day and total energy expenditure) were measured using an activity monitor at baseline (T0), and after 1 month (T1), 3 months (T3) 6 months (T6) of treatment.
Results: At T6 the PA of BT group (10 F; 59±10.12 years) was significantly improved compared to T0 (p<0.01), while in the TT group (8 F; 62,5±5,54 years) there wasn’t a significant difference between T6 and T0 (p=0.08) (Table 1). In the BT group, none of the PA parameters was significantly different comparing patients treated with mepolizumab and those with omalizumab.
Conclusions: These preliminary data show a positive relationship between the response to biologics in SA and PA levels, which could suggest a potential role of the PA pattern as a tool for the evaluation of the response to biologics.
Footnotes
Cite this article as: European Respiratory Journal 2019; 54: Suppl. 63, PA2754.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2019